At a glance
- Originator Aventis
- Class Anti-ischaemics; Heart failure therapies
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 19 Jan 2017 Discontinued - Preclinical for Ischaemic heart disorders in France